KYORIN Pharmaceutical (4569) · InitiativeAdvanced
Japanese Co-Development and License Agreement with Hinge Bio for HB2198 and Other SLE Candidates
First written in FY2026-H1. 2 of 3 entries say "Advanced", first in 2026-05-12. Latest entry: FY2026.
3entries
2years
1from disclosures
How it moved
Same theme, other companies
Japanese joint development and licensing agreement for HB2198 (KRP-A225) with HingeBioA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「In September 2025, the Company entered into a joint development and license agreement in Japan with ヒンジバイオ社, headquartered in the United States, for the novel therapeutic candidate KRP-A225, including for SLE and other indications. ヒンジバイオ社 is currently conducting a Phase 1 clinical trial.」
Following the execution of the joint development and license agreement in Japan for KRP-A225 in September 2025, development progressed to the stage at which the licensor was conducting a Phase 1 clinical trial. - 2026-05-12AdvancedFinancial results presentation
「KRP-A225 Ph1※」
KRP-A225, under a joint development and license agreement in Japan with HingeBio, was listed in the development pipeline at the Phase 1 stage. - FY2026-H1First statedAnnual report
「In September 2025, we entered into a co-development and license agreement with Hinge Bio for novel drug candidates for SLE and other indications in Japan.」
A Japanese co-development and license agreement for novel drug candidates for SLE and other indications, identified in the material contract as HB2198, was signed with Hinge Bio in September 2025. Consideration consists of an upfront fee, development and sales milestones, royalties and a supply price.